Vertex (VRTX) is a $76bn market cap, commercial stage pharmaceutical company based in the biotech heartland of Boston, Massachusetts. The company's success in growing revenues from $580m in 2014, to ...
Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results